Company / Return on Assets (ROA)
Acadia Pharmaceuticals Return on Assets (ROA) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Assets (ROA)
25.0%
FY2025
5-year range
-36.7% / 25.0%
FY2021-FY2025
Trend
+31.1%
vs FY2024
Sector context
#7 of 213
Health Care
What the data says
Among 213 Health Care companies, Acadia Pharmaceuticals is in the top 3% for return on assets (roa). Return on Assets (ROA) has increased for 3 consecutive years, from -36.7% in FY2022 to 25.0% in FY2025.
Based on SEC 10-K filings.
25.0% in FY2025 with a 5-year CAGR of +61.0%. Top quartile in the Health Care sector.
Improved from -8.2% to 25.0% over the past 2 years.
Health Care sector context is included.
Return on Assets (ROA) over time
Growth rates
- 3-Year Change
- +61.7pp
- 5-Year Change
- +61.0pp
- 10-Year Change
- -
Sector benchmark
+203.5% above sector average
Key checks
Key Insights
- Acadia Pharmaceuticals's return on assets (roa) has grown for 3 consecutive years.
- In FY2025, return on assets (roa) increased 31.1% year-over-year.
- Currently 49.2pp above the Health Care sector average.
- Lowest return on assets (roa) in the period was in FY2017.
Company context
Key Data Points
- Strong profit margin: 24.9%
- Low earnings quality (accrual-heavy earnings)
- Strong return on equity: 28.5%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Assets (ROA)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | 25.0% | +31.1% |
| FY2024 | 19.1% | +333.1% |
| FY2023 | -8.2% | +77.7% |
| FY2022 | -36.7% | -53.2% |
| FY2021 | -24.0% | +33.4% |
| FY2020 | -36.0% | -19.8% |
| FY2019 | -30.0% | +33.8% |
| FY2018 | -45.4% | +39.7% |
| FY2017 | -75.3% | -55.6% |
| FY2016 | -48.4% | +34.7% |
As of FY2025 · SEC 10-K · Updated Jul 1, 2026